Harvard Apparatus needs funding during Q1 2027
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Harvard Apparatus Regenerative Technology, Inc. reported third-quarter and nine-month 2026 results: product revenue was $145,000 for the quarter and $785,000 for nine months, up 18% and 62% from 2025. Nine-month net loss narrowed to $4.759 million from $5.182 million. In September, the company issued 2,513,250 shares at $1.05 per share for approximately $2.6 million in total consideration, including approximately $1.9 million in cash and settlement of related-party debt and interest.
The company had $1.851 million in cash at September 30 and expects it to fund operations and capital expenditures into the first quarter of 2027, assuming continued salary deferrals and no settlement of accrued unpaid salaries. It says substantial doubt about its ability to continue as a going concern remains and additional capital is needed; without outside funding during the first quarter of 2027, it may curtail or cease operations. Patient recruitment delays continue. After closing its University of Michigan trial site in September, Mayo Clinic is its only active clinical trial site.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNine-month product revenue rose 62% to $785,000.
- Moderate pointNine-month net loss narrowed 8% to $4.759 million.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Substantial doubt; $1.9 million cash expected into Q1 2027.
- Moderate pointHealth Regen accounted for approximately 100% of third-quarter product revenue.
Filing Explained
The 2,513,250 issued shares reduce existing holders’ ownership percentages, while about $1.0 million of deferred payroll remains unpaid pending financing.
This unaudited quarterly report says the
The share issuance increases the total share count and reduces existing holders’ percentage ownership, absent offsetting changes.
The notes converted at
Accrued payroll included about
Key Figures
Key Terms
substantial doubt financial
deferred revenue financial
Qualified Financing financial
anti-dilutive financial
contract research organization medical
Phase 1 clinical trial medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did HRGN report for the first nine months of 2026?
What were the terms of HRGN's September 2026 private placement?
How long does HRGN expect its cash to fund operations?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
For the quarterly period ended
For the transition period from to
Commission file number
Harvard Apparatus Regenerative Technology, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| | | |
| (State or Other Jurisdiction of | (IRS Employer | |
| Incorporation or Organization) | Identification No.) |
| | | |
| (Address of Principal Executive Offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| | Smaller reporting company |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
As of November 2, 2026, there were
Harvard Apparatus Regenerative Technology, Inc.
Form 10-Q
For the Quarter Ended September 30, 2026
INDEX
| Page |
||
| PART I-FINANCIAL INFORMATION |
5 |
|
| Item 1. |
Condensed Consolidated Financial Statements |
5 |
| Condensed Consolidated Balance Sheets |
5 |
|
| Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) |
6 |
|
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) |
7 |
|
| Condensed Consolidated Statements of Cash Flows (Unaudited) |
8 |
|
| Notes to Unaudited Condensed Consolidated Financial Statements |
9 |
|
| Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
22 |
| Item 3. |
Quantitative and Qualitative Disclosures about Market Risk |
29 |
| Item 4. |
Controls and Procedures |
29 |
| PART II-OTHER INFORMATION |
30 |
|
| Item 1. |
Legal Proceedings |
30 |
| Item 1A. |
Risk Factors |
30 |
| Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
30 |
| Item 3. |
Defaults Upon Senior Securities |
30 |
| Item 5. | Other Information | 30 |
| Item 6. |
Exhibits |
30 |
| SIGNATURES |
32 |
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that relate to future events, our future operations or financial performance, or our plans, strategies and prospects. These statements are based on the beliefs and assumptions of our management team. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or performance, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or the negative of these terms, or other comparable terminology intended to identify statements about the future, although not all forward-looking statements contain these identifying words. The forward-looking statements are based on projections prepared by, and are the responsibility of, our management team. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
● our ability to access debt and equity markets and raise additional capital when needed;
● plans and expectations that depend on our ability to continue as a going concern;
● the success of our collaborations, clinical trials and pre-clinical development efforts and programs, which success may not be achieved on a timely basis or at all;
● our ability to obtain and maintain regulatory approval for our implant products, bioreactors, scaffolds and other devices we pursue, including for the esophagus or airway, which approvals may not be obtained on a timely basis or at all;
● the number of patients who can be treated with our products;
● the amount and timing of costs associated with our development of implant products, bioreactors, scaffolds and other devices;
● our ability to comply with regulations and any changes in regulations;
● our ability to avoid or minimize unpredictable difficulties or delays in the development of new technology;
● the ability of our collaborators or other third parties we contract with, including with respect to conducting any clinical trial or pre-clinical development efforts, to devote sufficient time and resources to successfully carry out their duties or meet expected deadlines;
● our ability to implement our growth strategy;
● our ability to attract and retain qualified personnel and key employees and retain senior management;
● the availability and price of acceptable raw materials and components from third-party suppliers;
● the potential for liability exposure with respect to our products;
● our estimates regarding expenses, future revenue, capital requirements, cash runway and needs for additional financing;
● our ability to compete in the fields of regenerative medicine and bioengineering and in consumer health products, and the financial resources of our competitors;
● our financial performance;
● the effects of the control our principal stockholders can exert based on holding a majority of voting power;
● our intellectual property rights and our ability to protect or enforce these rights, and the impact on our business, results and financial condition if we are unsuccessful in doing so; and
● our ability to address economic downturns and political and market conditions beyond our control and their potential to adversely affect our business, financial condition and results of operations, including, but not limited to, increasing our expenses and cost of capital and adversely impacting our supply chain.
These forward-looking statements are based on information available as of the date of this report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results, performance or achievements to differ materially from those indicated or implied by forward-looking statements such as those described under the caption “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K, in Part II, Item 1A of this Quarterly Report on Form 10-Q, elsewhere herein and in other filings that we make from time to time with the U.S. Securities and Exchange Commission (the “SEC”). The risks described in such filings are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements.
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and par value data)
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable | ||||||||
| Inventory | ||||||||
| Prepaid research and development | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property, plant and equipment, net | ||||||||
| Right-of-use assets, net | ||||||||
| Long-term prepaid contracts | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued and other current liabilities | ||||||||
| Deferred revenue | ||||||||
| Insurance premium financing payable | ||||||||
| Operating lease liability | ||||||||
| Total current liabilities | ||||||||
| Operating lease liability, net of current portion | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 6) | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, par value $0.01 per share, 60,000,000 shares authorized; 20,093,994 and 17,580,744 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
See accompanying notes to unaudited condensed consolidated financial statements.
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(in thousands, except share and per share data)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Product revenue | $ | $ | $ | $ | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of sales | ||||||||||||||||
| Research and development | ||||||||||||||||
| Sales and marketing | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other (expense) income, net: | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income | ||||||||||||||||
| Other (expense) income, net | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic and diluted net loss per share | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common shares outstanding, basic and diluted | ||||||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Foreign currency translation adjustments | ( | ) | ( | ) | ||||||||||||
| Comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
See accompanying notes to unaudited condensed consolidated financial statements.
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
(in thousands, except share data)
| Number of | Accumulated | |||||||||||||||||||||||
| Common | Additional | Other | Total | |||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Loss | Equity (Deficit) | |||||||||||||||||||
| Balance at July 1, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||
| Share-based compensation expense | — | |||||||||||||||||||||||
| Issuance of common stock in private placement | ||||||||||||||||||||||||
| Conversion of convertible debt – related party and accrued interest into common stock | ||||||||||||||||||||||||
| Net loss | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Number of | Accumulated | |||||||||||||||||||||||
| Common | Additional | Other | Total | |||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Loss | Equity | |||||||||||||||||||
| Balance at July 1, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Share-based compensation expense | — | |||||||||||||||||||||||
| Issuance of common stock in private placement | ||||||||||||||||||||||||
| Net loss | — | ( | ) | ( | ) | |||||||||||||||||||
| Other comprehensive loss | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Number of | Accumulated | |||||||||||||||||||||||
| Common | Additional | Other | Total | |||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Loss | Equity | |||||||||||||||||||
| Balance at January 1, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Share-based compensation expense | — | |||||||||||||||||||||||
| Issuance of common stock in private placement | ||||||||||||||||||||||||
| Conversion of convertible debt – related party and accrued interest into common stock | ||||||||||||||||||||||||
| Net loss | — | ( | ) | ( | ) | |||||||||||||||||||
| Other comprehensive income | — | |||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Number of | Accumulated | |||||||||||||||||||||||
| Common | Additional | Other | Total | |||||||||||||||||||||
| Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ | |||||||||||||||||||
| Outstanding | Stock | Capital | Deficit | Loss | Equity | |||||||||||||||||||
| Balance at January 1, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Share-based compensation expense | — | |||||||||||||||||||||||
| Issuance of common stock in private placement | ||||||||||||||||||||||||
| Net loss | — | ( | ) | ( | ) | |||||||||||||||||||
| Other comprehensive loss | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
See accompanying notes to unaudited condensed consolidated financial statements.
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands)
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| OPERATING ACTIVITIES | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Share-based compensation expense | ||||||||
| Depreciation | ||||||||
| Amortization of operating lease right-of-use assets | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Inventory | ||||||||
| Prepaid research and development | ( | ) | ||||||
| Prepaid expenses and other current assets | ||||||||
| Long-term prepaid contracts | ( | ) | ||||||
| Accounts payable | ( | ) | ||||||
| Operating lease liability | ( | ) | ( | ) | ||||
| Accrued and other current liabilities | ||||||||
| Deferred revenue | ||||||||
| Insurance premium financing payable | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| FINANCING ACTIVITIES | ||||||||
| Proceeds from convertible debt – related party | ||||||||
| Proceeds from issuance of common stock in private placements | ||||||||
| Net cash provided by financing activities | ||||||||
| Effect of exchange rate changes on cash | ( | ) | ||||||
| Net increase (decrease) in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents at the beginning of the year | ||||||||
| Cash and cash equivalents at the end of the period | $ | $ | ||||||
| SUPPLEMENTAL INFORMATION | ||||||||
| Interest paid in cash | $ | $ | ||||||
| Non-cash financing activities: | ||||||||
| Conversion of convertible debt – related party and accrued interest into common stock | $ | $ | ||||||
See accompanying notes to unaudited condensed consolidated financial statements.
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Organization
Overview
Harvard Apparatus Regenerative Technology, Inc. (“Harvard Apparatus Regenerative Technology” or the “Company”) is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects. The Company believes its technology is likely to be used to repair wounds or other damage or defects resulting from esophageal cancer, esophageal injuries, and birth defects in the esophagus. The Company believes additional product candidates in its development pipeline may repair wounds or other damage or defects resulting from intestinal cancer and uterus wounds. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets.
Consumer Health Products
The Company’s subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or Consumer Health Products, focuses on sales of consumer health products.
Consumer Health Products includes a broad range of products focused on personal healthcare including dietary supplements. The Company currently sells dietary supplements through Consumer Health Products. These products are commercially marketed to the general public and initially targeted at consumers in Asia through eCommerce (online sales).
Going Concern
The Company has incurred substantial operating losses since its inception, and as of September 30, 2026, had an accumulated deficit of approximately $
The Company will need to raise additional capital to fund its current operations. In the event the Company is unable to raise additional capital from outside sources during the first quarter of 2027, it may be forced to curtail or cease its operations.
Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of product candidates, as well as regulatory efforts and collaborative arrangements necessary for the Company’s product candidates that are currently under development. The Company is currently seeking and will continue to seek financing from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. The Company may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. The Company may not be able to obtain additional financing on favorable terms, if at all.
The Company’s operations will be adversely affected if it is unable to raise or obtain needed funding and may materially affect the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and therefore, the condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.
2. Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements
Summary of Significant Accounting Policies
The accounting policies underlying the accompanying condensed consolidated financial statements are those set forth in Note 2 to the condensed consolidated financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2026 (the “Form 10-K”).
Principles of Consolidation
The condensed consolidated financial statements include the accounts of Harvard Apparatus Regenerative Technology and its subsidiaries: Harvard Apparatus Regenerative Technology Limited (Hong Kong), Harvard Apparatus Regenerative Technology (Hangzhou) Limited (China), Harvard Apparatus Regenerative Technology GmbH (Germany), and Harvard Apparatus Regenerative Technology Incorporated (California). All intercompany balances and transactions have been eliminated in consolidation.
Basis of Presentation
The condensed consolidated financial statements reflect the Company’s financial position, results of operations and comprehensive loss and cash flows in conformity with accounting principles generally accepted in the United States, or U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Form 10-K for the fiscal year ended December 31, 2025.
Use of Estimates
The process of preparing condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.
Revenue
The Company recognizes revenue in accordance with Financial Accounting Standards Board (“FASB”) ASC 606, Revenue from Contracts with Customers. The Company offers consumer products primarily through a third-party online store. Revenue is recognized at a point in time when control of the goods is transferred to the customer, which generally occurs upon the delivery to the customer. For any company direct sales to customers, revenue is recognized at a point in time upon shipment of product or hand-delivery to customer. In October 2024, the Company entered into an exclusive distribution agreement (the “Distribution Agreement”) with Health Regen, Inc., of Pittsfield, MA (“Health Regen”). Pursuant to the Distribution Agreement, the Company granted Health Regen exclusive distribution rights to all of its Consumer Health Products globally. For any sales to Health Regen, revenue is recognized when goods are made available by the Company for transfer. Revenue also excludes any amounts collected on behalf of third parties, including sales and indirect taxes.
The Company identifies a performance obligation as distinct if both the following criteria are true: the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. Determining the standalone selling price (“SSP”) and allocation of consideration from a contract to the individual performance obligations, and the appropriate timing of revenue recognition, is the result of significant qualitative and quantitative judgments. Management considers a variety of factors such as historical sales, usage rates, costs, and expected margin, which may vary over time depending upon the unique facts and circumstances related to each performance obligation in making these estimates. While changes in the allocation of the SSP between performance obligations will not affect the amount of total revenue recognized for a particular contract, any material changes could impact the timing of revenue recognition, which would have a material effect on the Company’s financial position and result of operations. This is because the contract consideration is allocated to each performance obligation, delivered or undelivered, at the inception of the contract based on the SSP of each distinct performance obligation.
Cost of Sales
Cost of sales primarily consists of the purchase price of consumer products, taxes, inbound and outbound shipping costs. Shipping costs to receive products from our suppliers are recognized as cost of sales when incurred. E-commerce processing and related transaction costs, including those associated with seller transactions, are classified in sales and marketing on our condensed consolidated statements of operations and comprehensive loss.
Research and Development
Research and development costs are expensed as incurred.
Sales and Marketing
Sales and marketing costs include advertising and payroll and related expenses for personnel engaged in marketing and selling activities. In October 2024, the Company entered into the Distribution Agreement with Health Regen, pursuant to which the Company granted Health Regen exclusive distribution rights to all of its Consumer Health Products globally. Health Regen primarily facilitates distribution in coordination with the Company’s Hong Kong subsidiary. The initial term of the Distribution Agreement is from November 1, 2024 through December 31, 2030.
General and Administrative
General and administrative expenses primarily consist of costs for corporate functions, including payroll and related expenses; facilities and equipment expenses, such as depreciation and amortization expense and rent; and professional fees.
Segment Information
The Company manages its operations as two separate operating segments for the purposes of assessing performance and making operating decisions. The Company has one operating unit focused on the development and commercialization of therapies to treat cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The other operating unit is focused on personal healthcare through dietary supplements. The Company has determined that its chief executive officer is the chief operating decision maker (the “CODM”). The CODM reviews separate discrete financial information presented by operating segment. Resource allocation decisions are made by the CODM based on operating segment cash used in operations, revenues and net income (loss).
Cash Concentrations
The Company maintains its cash balances at accredited financial institutions with high credit ratings. These balances are held in federally insured accounts, and from time to time the Company may maintain balances in excess of applicable insurance limits. The Company has not experienced any losses on its cash holdings to date and does not believe it is exposed to significant credit risk beyond the normal risks associated with commercial banking relationships. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation up to $250,000. As of September 30, 2026, approximately $
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company currently invests available cash in money market funds.
Accounts Receivable
Allowances for credit losses are provided for estimated amounts of accounts receivable which may not be collected. At September 30, 2026 and December 31, 2025, we determined that no allowance for credit losses against accounts receivable was necessary. The Company has elected the practical expedient under ASU 2025-05, which assumes current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. Advance payment is required under standard terms.
Inventory
Inventory, consisting of products available for sale, are primarily accounted for using the first-in, first-out method, and are valued at the lower of cost and net realizable value. This valuation requires us to make judgments, based on currently available information, about the likely method of disposition, such as through sales to individual customers, returns to product vendors, or liquidations, and expected recoverable values of each disposition category.
Long-term Prepaid Contracts
The Company has contracted with partners relating to its clinical trial activities. Upon execution of the contracts, the Company made initial deposits of $
Property, Plant and Equipment
Property, plant and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:
| Leasehold improvements | Shorter of expected useful life or lease term (years) | |||
| Computer equipment and software | ||||
| Furniture, machinery and equipment | ||||
Maintenance and repairs are charged to expense as incurred, while any additions or improvements are capitalized.
Impairment of Long-Lived Assets
Assessments of long-lived assets and the remaining useful lives of such long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An asset, or group of assets, are considered to be impaired when the undiscounted estimated net cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognized is the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the present value of the expected future cash flows associated with the use of the asset. Through September 30, 2026, no such impairment charges have been recorded.
Deferred Revenue
The Company does not recognize contract assets, as revenue is not recognized prior to the satisfaction of performance obligations and the right to consideration is unconditional at the time of invoicing. Deferred revenue represents advance payments received from our distributor for goods that will be made available to be transferred in future periods. These payments are initially recorded as liabilities and recognized as revenue when the related goods are provided. The Company had
Management regularly reviews the deferred revenue balance to ensure that revenue is recognized in accordance with the Company’s revenue recognition policy and applicable accounting standards.
The following table summarizes the Company’s contract balances from contracts with customers as required by ASC 606-10-50-8 in thousands:
| September 30, | December 31, | |||||||
| Contract Balances | 2026 | 2025 | ||||||
| Deferred revenue | $ | $ | ||||||
Foreign Currency
Assets and liabilities of non-U.S. operations where the functional currency is other than the U.S. dollar are translated from the functional currency into U.S. dollars at period-end exchange rates, and revenues and expenses are translated at average rates prevailing during the period. Resulting translation adjustments are accumulated as part of accumulated other comprehensive loss. Transaction gains or losses are recognized in income or loss in the period in which they occur.
Net Loss Per Share
Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method for stock options and warrants and the if-converted method for convertible debt. For purposes of the diluted net loss per share calculation, warrants to purchase the Company’s common stock, stock options and shares issuable upon conversion of the Bridge Notes are considered to be common stock equivalents, but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.
Concentration of Credit Risk
For the three and nine months ended September 30, 2026 and 2025, Health Regen accounted for approximately
Unaudited Interim Financial Information
The accompanying interim condensed consolidated balance sheet as of September 30, 2026, condensed consolidated interim statements of operations and comprehensive loss and condensed consolidated statements of stockholders’ equity (deficit) for the three and nine months ended September 30, 2026 and 2025, and cash flows for the nine months ended September 30, 2026 and 2025 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of September 30, 2026, its condensed consolidated results of operations and changes in stockholders’ equity (deficit) for the three and nine months ended September 30, 2026 and 2025, and cash flows for the nine months ended September 30, 2026 and 2025. The financial data and other information disclosed in these notes related to the three and nine months ended September 30, 2026 and 2025 are unaudited. The results for the three and nine months ended September 30, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026, any other interim periods or any future year or period.
Recent Accounting Pronouncements
Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s condensed consolidated financial statements upon adoption.
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 improves disclosures about a public business entity’s expenses by requiring disaggregated disclosures of certain types of expenses, including purchases of inventory, employee compensation, depreciation, intangible amortization and depletion, as applicable, for each income statement caption that includes those expenses. In addition, the standard will require entities to define and disclose total selling expenses. The standard is effective for public business entities for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted, and entities may apply the standard prospectively or retrospectively. The Company is currently evaluating the impact of adopting this standard on its condensed consolidated financial statements and related disclosures.
In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This update provides a practical expedient and an accounting policy election for estimating expected credit losses on current accounts receivable and contract assets arising under ASC 606. The Company adopted ASU 2025-05 effective January 1, 2026, applying the practical expedient, which assumes that current conditions as of the balance sheet date remain unchanged for the remaining life of the asset. The adoption did not have a material impact on the Company's condensed consolidated financial statements.
In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as induced conversions. ASU 2024-04 became effective for the Company on January 1, 2026 (annual periods beginning after December 15, 2025, and interim periods within those annual periods) and is applied prospectively to settlements of convertible debt instruments occurring on or after that date. The Company’s first settlement within the scope of ASU 2024-04 was the conversion of the Bridge Notes in the third quarter of 2026; no other convertible debt instruments were outstanding or settled during the nine months ended September 30, 2026. The adoption did not have a material impact on the Company’s condensed consolidated financial statements. See Note 7 for the conversion of the Bridge Notes during the third quarter of 2026.
Fair Value Measurements
There have been no material changes to the Company’s fair value measurement policies, methods, or financial instruments since the disclosures included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
3. Accrued and Other Current Liabilities
Accrued and other current liabilities consist of the following:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (in thousands) | ||||||||
| Advisory costs | $ | $ | ||||||
| Audit services | ||||||||
| Payroll | ||||||||
| Other liabilities | ||||||||
| Total accrued and other current liabilities | $ | $ | ||||||
Accrued payroll at September 30, 2026 includes approximately $
4. Capital Stock
Preferred Stock
The Company has authorized a total of
Common Stock
On September 11, 2026, the Company closed a private placement (the “September 2026 Private Placement”) pursuant to securities purchase agreements with certain investors, including the Company’s Chairman, Chief Executive Officer and Director and two other members of the Company’s Board of Directors (collectively, the “Inside Investors”), and outside investors, pursuant to which the investors purchased an aggregate of
On December 30, 2025, the Company entered into securities purchase agreements with certain investors pursuant to which the investors agreed to purchase in a private placement an aggregate of
On July 11, 2025, the Company entered into securities purchase agreements with certain investors pursuant to which the investors agreed to purchase in a private placement an aggregate of
Warrants
The Company had
5. Share-Based Compensation
Harvard Apparatus Regenerative Technology Amended and Restated Equity Incentive Plan
The Company maintains the Amended and Restated Equity Incentive Plan, or the Plan, for the benefit of certain officers, employees, non-employee directors, and other key persons (including consultants and advisory board members). All options and awards granted under the Plan consist of shares of common stock. The Company’s policy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercises and the vesting of restricted stock units. The vesting period for awards is generally four years and the contractual life is ten years. Canceled and forfeited options and awards are available to be reissued under the Plan.
As of September 30, 2026, the Company’s Plan has
The following table summarizes information concerning options outstanding and exercisable:
| Weighted- | Weighted- | Aggregate | ||||||||||||||
| average | average | intrinsic | ||||||||||||||
| exercise | remaining contractual | value | ||||||||||||||
| Amount | price | life (years) | (in thousands) | |||||||||||||
| Outstanding at December 31, 2025 | $ | $ | ||||||||||||||
| Granted | ||||||||||||||||
| Outstanding at September 30, 2026 | ||||||||||||||||
| Options exercisable | ||||||||||||||||
| Options vested and expected to vest | ||||||||||||||||
Total unrecognized compensation expense for the remaining
During the nine months ended September 30, 2026, the Company determined that the performance conditions for certain performance-based awards were probable of achievement or were achieved and recognized cumulative catch-up adjustments to share-based compensation expense of $
On July 21, 2026, the Company granted its Chairman and Chief Executive Officer a nonqualified stock option under the Plan to purchase
Aggregate intrinsic value for outstanding options as of September 30, 2026 was approximately $
The weighted average assumptions for valuing the Company's stock options granted were as follows:
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Risk-free interest rate | % | % | ||||||
| Expected volatility | % | % | ||||||
| Expected term (in years) | ||||||||
| Expected dividend yield | % | % | ||||||
The weighted average estimated fair value of stock options granted using the Black-Scholes model was $
The Company recorded share-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| (In thousands) | (In thousands) | |||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
6. Commitments and Contingencies
From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that the Company expects to be material in relation to its business, financial condition, results of operations, or cash flows.
On August 12, 2024, the Company entered into an operating lease agreement for approximately
In April 2025, the Company entered into a Master Service Agreement with uBriGene (Boston) Biosciences, Inc., a contract development and manufacturing organization, pursuant to which uBriGene will provide development, manufacturing, and related regulatory support services for the Company’s investigational programs. Services are performed under statements of work and are milestone‑based. Under the applicable statement of work, contractual milestones include: (i) execution of the agreement and initiation of technology transfer activities; (ii) completion of multiple technology transfer production runs and related quality control testing; (iii) completion of stability testing using materials produced from the technology transfer runs; (iv) initiation of investigational batch production; and (v) completion of investigational batch production and associated regulatory support activities. Fees are payable upon the achievement of these milestones. The Company may terminate the agreement or any statement of work upon prior written notice. Upon termination, the Company is not obligated to pay for services not performed prior to the effective date of termination but remains responsible for amounts incurred for services performed and certain non‑cancelable costs. Payments made in advance of services being rendered are recorded as prepaid expenses and expensed as the related services are performed.
As of September 30, 2026, the Company had no minimum remaining non‑cancelable purchase commitments under this agreement, as all future payments are contingent upon the achievement of development and manufacturing milestones and the Company’s authorization of continued services.
On July 1, 2025, the Company entered into a services agreement with Beijing Quarkmed Technology Co., Ltd. with a total contract value of approximately $
In November 2025, the Company entered into an insurance premium financing and security agreement. Under the agreement, the Company financed $
7. Convertible Debt – Related Party
Convertible Debt
On April 13, 2026, May 8, 2026 and July 16, 2026, the Company entered into loan arrangements with Junli He, the Chairman, Chief Executive Officer, and Director of the Company (the “Lender”), pursuant to which the Lender loaned the Company an aggregate amount of $
The Bridge Notes accrued interest at an annual fixed rate of
On September 11, 2026, the September 2026 Private Placement (Note 4) constituted a Qualified Financing and the Lender elected to convert the entire outstanding balance of the Bridge Notes, consisting of principal of $
8. Leases
The Company leases laboratory and office space and certain equipment with a remaining term of approximately one year.
On August 12, 2024, the Company entered into the HQ Lease, an operating lease agreement for laboratory and office space in Holliston, MA, with an initial three-year term from September 1, 2024 through August 31, 2027. The Company accounts for the HQ Lease in accordance with ASC Topic 842, Leases. The Company recorded approximately $
The HQ Lease contains escalating payments during the lease term. Upon execution of the HQ Lease, the Company paid a security deposit, which will be held in escrow and credited at the termination of the lease. As of September 30, 2026, a security deposit of approximately $
All of the Company’s leases qualify as operating leases. The following table summarizes the presentation of the Company’s operating leases in its condensed consolidated balance sheets:
| September 30, | December 31, | ||||||||
| Balance Sheet Classification | 2026 | 2025 | |||||||
| Assets: | |||||||||
| Operating lease assets | Right-of-use assets, net | $ | $ | ||||||
| Liabilities: | |||||||||
| Current portion of operating lease liability | Operating lease liability | ||||||||
| Operating lease liability, net of current portion | Operating lease liability, net of current portion | ||||||||
| Total operating lease liability | $ | $ | |||||||
The Company recorded operating lease expense in the following categories in its condensed consolidated statements of operations and comprehensive loss:
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||
Cash paid included in the computation of the operating lease assets and lease liability during the three and nine months ended September 30, 2026 amounted to approximately $
The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:
| As of September 30, | ||||||||
| 2026 | 2025 | |||||||
| Remaining lease term (in years) | ||||||||
| Discount rate | % | % | ||||||
The minimum lease payments for future years are as follows:
| As of | ||||
| September 30, | ||||
| 2026 | ||||
| (in thousands) | ||||
| 2026 | $ | |||
| 2027 | ||||
| Total lease payments | ||||
| Less: imputed interest | ( | ) | ||
| Present value of operating lease liability | $ | |||
9. Net Loss Per Share
The following potential common shares were excluded from the calculation of diluted net loss per share attributable to common stockholders for the nine months ended September 30, 2026 and 2025 because including them would have had an anti-dilutive effect:
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Options to purchase common stock | ||||||||
| Warrants to purchase common stock | ||||||||
| Total | ||||||||
The
10. Income Taxes
The Company did not record a federal or state income tax provision or benefit for the three and nine months ended September 30, 2026 and 2025 due to the expected loss before income taxes to be incurred for the years ended December 31, 2026 and 2025, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets.
11. Segments
The Company’s CODM is its Chief Executive Officer. The Company’s CODM evaluates the operating results of the Company’s reportable segments based on cash used in operations, revenues and segment net (loss) income.
The Company follows the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the CODM organizes the segments within an enterprise for making operating decisions and assessing performance. While the Company’s results of operations are primarily reviewed on a consolidated basis, the CODM manages the enterprise in two reportable segments, each with different operating and potential revenue generating characteristics.
The Company has two operating and reportable segments: (i) Regenerative Biotech focused on the development of regenerative medicine treatments with operations currently in the United States and (ii) Consumer Health Products relating to consumer health products with operations currently in Asia. All of the Company’s revenue was generated in Asia for the three and nine months ended September 30, 2026 and 2025. The following tables present segment revenues, significant expense categories provided to the Company’s CODM at least quarterly, other segment items, and segment net (loss) income for the three and nine months ended September 30, 2026 and 2025, in thousands:
| Three Months Ended September 30, 2026 | ||||||||||||
| Regenerative Biotech | Consumer Health Products | Consolidated Total | ||||||||||
| Revenue | ||||||||||||
| Product revenue | $ | $ | $ | |||||||||
| Significant Expense Categories (provided to CODM) | ||||||||||||
| Cost of sales | ||||||||||||
| Research and development | ||||||||||||
| Sales and marketing | ||||||||||||
| General and administrative (a) | ||||||||||||
| Total significant segment expenses | ||||||||||||
| Other Segment Items | ||||||||||||
| Other segment items (b) | ( | ) | ( | ) | ||||||||
| Segment net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Three Months Ended September 30, 2025 | ||||||||||||
| Regenerative Biotech | Consumer Health Products | Consolidated Total | ||||||||||
| Revenue | ||||||||||||
| Product revenue | $ | $ | $ | |||||||||
| Significant Expense Categories (provided to CODM) | ||||||||||||
| Cost of sales | ||||||||||||
| Research and development | ||||||||||||
| Sales and marketing | ||||||||||||
| General and administrative (a) | ||||||||||||
| Total significant segment expenses | ||||||||||||
| Other Segment Items | ||||||||||||
| Other segment items (b) | ||||||||||||
| Segment net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Nine Months Ended September 30, 2026 | ||||||||||||
| Regenerative Biotech | Consumer Health Products | Consolidated Total | ||||||||||
| Revenue | ||||||||||||
| Product revenue | $ | $ | $ | |||||||||
| Significant Expense Categories (provided to CODM) | ||||||||||||
| Cost of sales | ||||||||||||
| Research and development | ||||||||||||
| Sales and marketing | ||||||||||||
| General and administrative (a) | ||||||||||||
| Total significant segment expenses | ||||||||||||
| Other Segment Items | ||||||||||||
| Other segment items (b) | ( | ) | ( | ) | ||||||||
| Segment net (loss) income | $ | ( | ) | $ | $ | ( | ) | |||||
| Nine Months Ended September 30, 2025 | ||||||||||||
| Regenerative Biotech | Consumer Health Products | Consolidated Total | ||||||||||
| Revenue | ||||||||||||
| Product revenue | $ | $ | $ | |||||||||
| Significant Expense Categories (provided to CODM) | ||||||||||||
| Cost of sales | ||||||||||||
| Research and development | ||||||||||||
| Sales and marketing | ||||||||||||
| General and administrative (a) | ||||||||||||
| Total significant segment expenses | ||||||||||||
| Other Segment Items | ||||||||||||
| Other segment items (b) | ||||||||||||
| Segment net (loss) income | $ | ( | ) | $ | $ | ( | ) | |||||
The following table presents cash and cash equivalents and total assets by segment as of September 30, 2026 and December 31, 2025, in thousands:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Cash and cash equivalents: | ||||||||
| Regenerative Biotech | $ | $ | ||||||
| Consumer Health Products | ||||||||
| Total | $ | $ | ||||||
| Total assets: | ||||||||
| Regenerative Biotech | $ | $ | ||||||
| Consumer Health Products | ||||||||
| Total | $ | $ | ||||||
(a) Certain general and administrative costs (including executive compensation, corporate legal fees, audit fees, investor relations, and insurance) are shared across both segments. For internal reporting purposes, such costs are allocated to each segment based on an estimate of the proportion of management time and corporate resources utilized by each segment. Costs directly attributable to a segment are charged directly to that segment. For the three and nine months ended September 30, 2026 and 2025, the Regenerative Biotech segment bore substantially all general and administrative expense, as the Consumer Health Products segment incurred minimal shared corporate overhead.
(b) “Other segment items” for the Regenerative Biotech segment consists of interest income earned on money market balances, sublease and other miscellaneous income, and interest expense on the related-party Bridge Notes and insurance premium financing. For the three and nine months ended September 30, 2026, interest expense exceeded interest and other income, resulting in net other expense for the segment; for the three and nine months ended September 30, 2025, other segment items represented net other income. For the Consumer Health Products segment, other segment items consist of foreign currency transaction effects and other minor income items. The other segment items line represents the arithmetic difference between segment revenues, less the significant expense categories disclosed above, and the reported segment net (loss) income, in accordance with ASC 280-10-50-26B.
12. Subsequent Events
The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and, other than the matter described below and as disclosed elsewhere in these notes, did not identify any subsequent events requiring recognition or disclosure.
On October 14, 2026, the Company, through its wholly-owned subsidiary Harvard Apparatus Regenerative Technology Limited (Hong Kong), formed Hazai Technology (Shenzhen) Co., Ltd., a wholly-owned subsidiary organized under the laws of the People’s Republic of China. As of the date these condensed consolidated financial statements were issued, the subsidiary had not commenced operations and no capital had been contributed.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward Looking Statements
The following section of this Quarterly Report on Form 10-Q entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains statements that are not statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.
In some cases, you can identify forward-looking statements by terms such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “could,” “would,” “target,” “seek,” “aim,” “predicts,” “think,” “objectives,” “optimistic,” “new,” “goal,” “strategy,” “potential,” “likely,” “will,” “expect,” “plan,” “project,” “permit” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on March 19, 2026. You should carefully review all of these factors, as well as the comprehensive discussion of forward-looking statements on page 3 of this Quarterly Report on Form 10-Q.
Harvard Apparatus Regenerative Technology, Inc. is referred to herein as “we,” “our,” “us,” and “the Company”.
Business Overview
We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs that result from cancer, trauma or birth defects.
Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrificing of another of the patient’s own organs or permanent artificial implants.
Our first esophageal product candidate, our esophageal implant, was used in the first successful regeneration of the esophagus in a patient with esophageal cancer. This successful first-in-human experience, plus the research we have performed on over 50 pigs, led the FDA to approve our 10-patient Phase 1 clinical trial. This combination trial will measure both safety and efficacy in the patient population.
We have contracted with IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (“CRO”) to manage our first clinical trial. We activated the first clinical trial site and started screening patients in the third quarter of 2023.
We have encountered delays in patient recruitment for our ongoing clinical trial, driven by several factors, including the existing comorbid conditions for clinical trial participants, the stringent eligibility criteria required by the FDA for our studies, and logistical difficulties in enrolling participants. In September 2026, we closed our clinical trial site at the University of Michigan. No patients had been enrolled at that site, and we determined that the continuing cost of maintaining it was not warranted. Mayo Clinic is now our only active clinical trial site.
Although we are actively implementing strategies to mitigate these challenges, such as enhancing patient outreach efforts and concentrating our resources on our remaining clinical trial site, there is a risk that these measures may not completely resolve the recruitment issues. Our product candidates are currently in development and have not yet received regulatory approval for sale anywhere in the world.
In addition to our development of regenerative medicine treatments, we also sell dietary supplements. Our subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or Consumer Health Products, focuses on sales of consumer health products. Consumer Health Products plans to include a broad range of products focused on personal healthcare including dietary supplements. These products are commercially marketed to the general public and initially targeted at consumers in Asia through eCommerce (online sales).
We were incorporated and commenced operations on November 1, 2013 as a result of a spin-off from Harvard Bioscience, Inc., or Harvard Bioscience. On that date, we became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution of all the shares of common stock of Harvard Apparatus Regenerative Technology to Harvard Bioscience stockholders.
We continue to assess the market and regulatory approval pathway in China as to our implant products. We are not certain at this time as to which market, including U.S. or China for example, may provide the most viable initial pathway for regulatory approval to a commercial product. This will depend on a number of factors, including the approval and development processes, related costs, ability to raise capital and the terms and conditions thereof, among other factors. Any development and capital raising efforts in China may include a joint venture in relation to our Hong Kong subsidiary, and would also involve a number of commercial variables, including rights and obligations pertaining to licensing, development, and financing, among others. Our failure to receive or obtain such clearances or approvals on a timely basis or at all, whether that be in the U.S., China or otherwise, would have an adverse effect on our results of operations.
Since our incorporation, we have devoted substantially all of our resources to developing our programs, building our intellectual property portfolio, business planning, raising capital and providing selling, general and administrative support for these operations. To date, we have financed our operations with proceeds from the sales of common stock, preferred stock and warrants and, in 2026, the issuance of convertible notes to our Chief Executive Officer that were converted into common stock.
Business Segments
We have two separate reportable segments. One segment, Harvard Apparatus Regenerative Technology, Inc., or Regenerative Biotech, is focused on the development and commercialization of therapies to treat cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The other segment, Consumer Health Products, is focused on personal healthcare, including dietary supplements.
Financial Condition and Need for Additional Funds
We expect to continue to incur operating losses and negative cash flows from operations during 2026 and in future years.
Operating Losses and Cash Requirements
We have incurred substantial operating losses since our inception, and as of September 30, 2026, had an accumulated deficit of approximately $111.3 million and will require additional financing to fund future operations. We expect that our cash on hand as of September 30, 2026 of approximately $1.9 million will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2027, based on our current cash flow forecast, which assumes continued deferral of a portion of salaries and no settlement of accrued but unpaid salaries. We expect to continue to incur operating losses and negative cash flows from operations for 2026 and in future years. Therefore, as disclosed in Note 1 to our Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q, these conditions raise substantial doubt about our ability to continue as a going concern.
We will need to raise additional capital to fund our current operations. In the event we do not raise additional capital from outside sources during the first quarter of 2027, we may be forced to curtail or cease our operations.
Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of product candidates, as well as regulatory efforts and collaborative arrangements necessary for our product candidates that are currently under development. We are currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. We may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. We may not be able to obtain additional financing on favorable terms, if at all.
Our operations will be adversely affected if we are unable to raise or obtain needed funding and may materially affect our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and therefore, the condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.
Components of Operating Loss
Product revenue. Product revenue consists of consumer health product sales in the Asia region.
Research and development expense. Research and development expense consists of salaries and related expenses, including share-based compensation, for personnel and contracted consultants and various materials and other costs to develop our new products, primarily: synthetic scaffolds, including investigation and development of materials and investigation and optimization of cellularization, as well as studies of cells and cell behavior. Other research and development expenses include the costs of outside service providers and material costs for prototype and test units and outside laboratories and testing facilities performing cell growth and materials experiments, as well as the costs of all other preclinical research and testing including animal studies and expenses related to potential patents. We expense research and development costs as incurred.
Sales and marketing expense. Sales and marketing costs include advertising and payroll and related expenses for personnel engaged in marketing and selling activities.
General and administrative expense. General and administrative expense consists primarily of salaries and other related expenses, including share-based compensation. Other costs include professional fees for legal and accounting services, insurance, investor relations and facility costs.
Other (expense) income, net. Other (expense) income, net consists primarily of interest on the related-party bridge notes and finance charges on insurance installment payments, offset by sublease income, interest income and other miscellaneous income.
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.
While our significant accounting policies are discussed in more detail in Note 2 to our Condensed Consolidated Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.
Share-based Compensation
We account for our share-based compensation in accordance with the fair value recognition provisions of current authoritative guidance. Share-based awards, including stock options, are measured at fair value as of the grant date and recognized as expense over the requisite service period (generally the vesting period), which we have elected to amortize on a straight-line basis. Expense on share-based awards for which vesting is performance or milestone based is recognized on a straight-line basis from the date when we determine the achievement of the milestone is probable to the vesting/milestone achievement date. We account for forfeitures as they occur. We estimate the fair value of options granted using the Black-Scholes option valuation model. Significant judgment is required in determining the proper assumptions used in this model. The assumptions used include the risk-free interest rate, expected term, expected volatility, and expected dividend yield. We base our assumptions on historical data when available or, when not available, on a peer group of companies. However, these assumptions consist of estimates of future market conditions, which are inherently uncertain and subject to our judgment, and therefore any changes in assumptions could significantly impact the future grant date fair value of share-based awards.
Results of Operations
The following table summarizes the results of our operations for the three and nine months ended September 30, 2026 and 2025 (in thousands):
| Three Months |
Nine Months |
|||||||||||||||||||||||||||||||
| Ended |
Change 2026 |
Ended |
Change 2026 |
|||||||||||||||||||||||||||||
| September 30, |
vs. 2025 |
September 30, |
vs. 2025 |
|||||||||||||||||||||||||||||
| 2026 |
2025 |
Change |
% | 2026 |
2025 |
Change |
% | |||||||||||||||||||||||||
| Product revenue |
$ | 145 | $ | 123 | $ | 22 | 18 | % | $ | 785 | $ | 485 | $ | 300 | 62 | % | ||||||||||||||||
| Operating expenses |
||||||||||||||||||||||||||||||||
| Cost of sales |
133 | 112 | 21 | 19 | % | 730 | 447 | 283 | 63 | % | ||||||||||||||||||||||
| Research and development |
218 | 655 | (437 | ) | (67 | %) | 1,729 | 1,953 | (224 | ) | (11 | %) | ||||||||||||||||||||
| Sales and marketing |
17 | 25 | (8 | ) | (32 | %) | 51 | 35 | 16 | 46 | % |
|||||||||||||||||||||
| General and administrative |
1,237 | 1,045 | 192 | 18 | % | 3,033 | 3,267 | (234 | ) | (7 | %) | |||||||||||||||||||||
| Total operating expenses |
1,605 | 1,837 | (232 | ) | (13 | %) | 5,543 | 5,702 | (159 | ) | (3 | %) | ||||||||||||||||||||
| Other (expense) income, net: |
||||||||||||||||||||||||||||||||
| Interest income |
— | 11 | (11 | ) | (100 | %) | 2 | 31 | (29 | ) | (94 | %) | ||||||||||||||||||||
| Interest expense |
(13 | ) | (2 | ) | (11 | ) | (550 | %) | (23 | ) | (7 | ) | (16 | ) | (229 | %) | ||||||||||||||||
| Other income |
10 | 5 | 5 | 100 | % | 20 | 11 | 9 | 82 | % | ||||||||||||||||||||||
| Total other (expense) income, net |
(3 | ) | 14 | (17 | ) | NM | (1 | ) | 35 | (36 | ) | NM | ||||||||||||||||||||
| Net loss |
$ | (1,463 | ) | $ | (1,700 | ) | $ | 237 | 14 | % | $ | (4,759 | ) | $ | (5,182 | ) | $ | 423 | 8 | % |
||||||||||||
NM indicates that the percentage change is not meaningful.
Comparison of the three months ended September 30, 2026 and 2025
Product Revenue
Product revenue was $145,000 and $123,000 for the three months ended September 30, 2026 and 2025, respectively. The $22,000 increase, representing 18% growth, reflected continued shipments to Health Regen under the Distribution Agreement. Revenue is recognized when goods are made available to Health Regen for transfer; customer prepayments for orders not yet shipped are recorded in deferred revenue, which increased to $690,000 at September 30, 2026 from $252,000 at December 31, 2025.
Cost of Sales
Cost of sales was $133,000 and $112,000 for the three months ended September 30, 2026 and 2025, respectively. The increase is consistent with higher product shipments; cost of sales was 92% and 91% of product revenue for the three months ended September 30, 2026 and 2025, respectively.
Research and Development Expense
Research and development expense decreased approximately 67%, to approximately $0.2 million for the three months ended September 30, 2026 as compared to approximately $0.7 million for the three months ended September 30, 2025. The decrease was primarily attributable to lower clinical trial costs, including a vendor credit of approximately $184,000 issued by our CRO on August 13, 2026 for overcharges on a June 2026 invoice, which more than offset third-quarter CRO fees, the absence of clinical and regulatory consulting costs incurred in the prior-year period and lower preclinical study costs, partially offset by higher patent prosecution costs and scientific advisory board fees.
Sales and Marketing Expense
Sales and marketing expense was approximately $17,000 and $25,000 for the three months ended September 30, 2026 and 2025, respectively, consisting of sales personnel and promotional costs of our Consumer Health Products segment.
General and Administrative Expense
General and administrative expense increased approximately 18%, to approximately $1.2 million for the three months ended September 30, 2026 as compared to approximately $1.0 million for the three months ended September 30, 2025. The increase was attributable to higher share-based compensation expense of approximately $0.7 million compared to approximately $0.4 million in the prior-year period, including a cumulative catch-up of $382,524 recognized upon achievement of the $10.0 million cumulative capital-raising milestone on performance-based options held by our Chief Executive Officer and expense on the July 2026 option grant to our Chief Executive Officer (see Note 5). Excluding share-based compensation, general and administrative expense decreased approximately $48,000, primarily due to lower insurance premiums, travel and legal costs.
Interest income
During the three months ended September 30, 2026, interest income was de minimis, as compared to approximately $11,000 earned from our money market account during the three months ended September 30, 2025.
Interest expense
During the three months ended September 30, 2026 and 2025, we recorded interest expense of approximately $13,000 and $2,000, respectively, consisting of approximately $11,000 of interest accrued on the related-party bridge notes through their conversion on September 11, 2026 and finance charges on insurance installment payments.
Other income
For the three months ended September 30, 2026 and 2025, we recorded approximately $10,000 and $5,000, respectively, in other income, consisting of sublease income of approximately $5,000 in each period and, in 2026, approximately $5,000 of miscellaneous receipts. The sublease is part of our ongoing efforts to optimize the use of our facilities.
Comparison of the nine months ended September 30, 2026 and 2025
Product Revenue
Product revenue was $785,000 and $485,000 for the nine months ended September 30, 2026 and 2025, respectively. The $300,000 increase, representing 62% growth, was driven by an increase in shipments under the Distribution Agreement with Health Regen, including expanded distribution and new product launches within our Consumer Health Products segment, such as CoQ-10 and sleep aid gummies, alongside continued performance from our existing offerings such as Liver Guard.
Cost of Sales
Cost of sales was $730,000 and $447,000 for the nine months ended September 30, 2026 and 2025, respectively. The increase reflects higher shipment volumes; cost of sales was 93% and 92% of product revenue for the nine months ended September 30, 2026 and 2025, respectively.
Research and Development Expense
Research and development expense decreased approximately 11%, to approximately $1.7 million for the nine months ended September 30, 2026 as compared to approximately $2.0 million for the nine months ended September 30, 2025. The decrease was primarily attributable to lower preclinical study costs, which in the prior-year period included colon and uterus studies at academic institutions, lower clinical trial costs, reflecting the August 2026 CRO vendor credit of approximately $184,000, and lower patent costs, partially offset by higher clinical and regulatory consulting costs, higher scientific advisory board fees and higher share-based compensation expense of approximately $0.3 million compared to approximately $0.2 million, including a $194,870 cumulative catch-up recognized in the first quarter of 2026 on performance-based options that vested upon treatment of the first patient in our clinical trial.
Sales and Marketing Expense
Sales and marketing expense increased approximately 46%, to approximately $51,000 for the nine months ended September 30, 2026 as compared to approximately $35,000 for the nine months ended September 30, 2025. The increase reflects a full nine months of sales personnel and promotional costs in our Consumer Health Products segment.
General and Administrative Expense
General and administrative expense decreased approximately 7%, to approximately $3.0 million for the nine months ended September 30, 2026 as compared to approximately $3.3 million for the nine months ended September 30, 2025. The decrease was primarily attributable to lower insurance premiums following the 2025 renewal, lower public company, travel and legal costs and lower employee benefit costs, while share-based compensation expense included in general and administrative expense decreased slightly to approximately $1.3 million from approximately $1.4 million in the prior-year period.
Interest income
During the nine months ended September 30, 2026 and 2025, we recorded interest income of approximately $2,000 and $31,000, respectively, earned from our money market account; the decrease reflects lower average cash balances during 2026.
Interest expense
During the nine months ended September 30, 2026 and 2025, we recorded interest expense of approximately $23,000 and $7,000, respectively, consisting of approximately $18,000 of interest accrued on the related-party bridge notes in the 2026 period, which was settled in shares upon conversion on September 11, 2026, and finance charges on insurance installment payments.
Other income
For the nine months ended September 30, 2026 and 2025, we recorded approximately $20,000 and $11,000, respectively, in other income, consisting primarily of sublease income of approximately $14,000 and $7,000, respectively, and miscellaneous receipts. The sublease is part of our ongoing efforts to optimize the use of our facilities.
Liquidity and Capital Resources
Sources of liquidity. We have incurred operating losses since inception, and as of September 30, 2026, we had an accumulated deficit of approximately $111.3 million. We are currently investing significant resources in the development and commercialization of our product candidates for use by clinicians and researchers in the fields of regenerative medicine and bioengineering. As a result, we expect to incur operating losses and negative operating cash flows for the foreseeable future. Therefore, as disclosed in Note 1 to our Condensed Consolidated Financial Statements, these conditions raise substantial doubt about our ability to continue as a going concern. On September 11, 2026, we closed the September 2026 Private Placement of 2,513,250 shares of our common stock at $1.05 per share for aggregate consideration of approximately $2.6 million, including approximately $0.7 million of related-party bridge notes and accrued interest settled in shares, as described in Notes 4 and 7 to our Condensed Consolidated Financial Statements.
The following table sets forth the primary sources and uses of cash for the nine months ended September 30, 2026 and 2025 (in thousands):
| Nine Months Ended |
||||||||
| September 30, |
||||||||
| 2026 |
2025 |
|||||||
| Net cash used in operating activities |
$ | (2,127 | ) | $ | (3,164 | ) | ||
| Net cash provided by financing activities |
$ | 2,621 | $ | 2,000 | ||||
Comparison of the nine months ended September 30, 2026 and 2025
Operating activities. Net cash used in operating activities of approximately $2.1 million for the nine months ended September 30, 2026 was due primarily to our net loss of approximately $4.8 million offset by adjustments for non-cash items of approximately $1.7 million due to non-cash expenses for share-based compensation, depreciation and amortization, and an approximately $1.0 million increase to cash from changes in working capital, primarily higher accrued liabilities, including accrued payroll, and higher deferred revenue, partially offset by an increase in long-term prepaid contracts and prepaid research and development and payments on insurance premium financing.
Net cash used in operating activities of approximately $3.2 million for the nine months ended September 30, 2025 was due primarily to our net loss of approximately $5.2 million offset by adjustments for non-cash items of approximately $1.6 million due to non-cash expenses for share-based compensation, depreciation and amortization, and an approximately $0.4 million increase to cash from changes in working capital due to the timing of payments for accounts receivable, inventory, prepaid expenses, long-term prepaid contracts, accounts payable, deferred revenue, insurance premium financing and accrued expenses.
Financing activities. Net cash provided by financing activities was approximately $2.6 million for the nine months ended September 30, 2026, consisting of $700,000 of proceeds from bridge loans from Junli He, our Chairman, Chief Executive Officer, and Director, evidenced by bridge notes bearing interest at an annual fixed rate of 8%, all of which were converted into shares of our common stock on September 11, 2026, and approximately $1.9 million of cash proceeds from the September 2026 Private Placement. Net cash provided by financing activities was approximately $2.0 million for the nine months ended September 30, 2025, consisting of proceeds from the July 2025 private placement of 1,250,000 shares of common stock.
Off-Balance Sheet Arrangements
We do not have any material off-balance sheet arrangements as of September 30, 2026.
Other Information
None.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
The Company is a smaller reporting company and is not required to provide this information pursuant to Item 305(e), Regulation S-K.
Item 4. Controls and Procedures.
This Report includes the certifications of our principal executive officer and our principal financial and accounting officer required by Rule 13a-14 of the Exchange Act. See Exhibits 31.1 and 31.2.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chairman, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial and accounting officer, to allow timely decisions regarding required disclosures.
In connection with the preparation of this Quarterly Report on Form 10-Q, our management, under the supervision and with the participation of our principal executive officer and our principal financial and accounting officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026. Based upon the evaluation described above, our principal executive officer and our principal financial and accounting officer have concluded that they believe our disclosure controls and procedures were effective as of the end of the period covered by this report, in providing reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial and accounting officer, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.
Changes in Internal Control over Financial Reporting
Our management, with the participation of our principal executive officer and our principal financial and accounting officer, has evaluated whether any change in our internal control over financial reporting occurred during the quarter ended September 30, 2026. During the period covered by this report, we have concluded that there were no changes during the fiscal quarter in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that we expect to be material in relation to our business, financial condition, and results of operations or cash flows.
Item 1A. Risk Factors
To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form 10-Q relates to such risk factors, there have been no material changes in the risk factors described in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 19, 2026.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On September 11, 2026, we issued an aggregate of 2,513,250 shares of our common stock at a purchase price of $1.05 per share to six accredited investors, including our Chairman and Chief Executive Officer and two of our directors, in a private placement for aggregate consideration of approximately $2.6 million, consisting of approximately $1.9 million in cash and the settlement of $717,911 of principal and accrued interest under bridge notes held by our Chief Executive Officer. The shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated thereunder. No underwriters were involved and no commissions were paid. We intend to use the net cash proceeds for working capital and general corporate purposes, including our ongoing clinical trial. The issuance was previously reported in our Current Report on Form 8-K filed on September 14, 2026.
We did not repurchase any of our equity securities during the three months ended September 30, 2026.
Item 3. Defaults Upon Senior Securities
None.
Item 5. Other Information
(c) During the three months ended September 30, 2026, no directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Item 6. Exhibits
| Exhibit Index |
||
|
|
|
|
| 10.1 | Bridge Note dated July 16, 2026 executed by Harvard Apparatus Regenerative Technology, Inc. payable to the order of Junli He (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on August 3, 2026, and incorporated by reference thereto). | |
| 10.2+ | Form of Securities Purchase Agreement, dated September 11, 2026, between Harvard Apparatus Regenerative Technology, Inc. and the investors named therein (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on September 14, 2026, and incorporated by reference thereto). | |
| 10.3*# | Nonqualified Stock Option Agreement, dated July 21, 2026, between Harvard Apparatus Regenerative Technology, Inc. and Junli He. | |
| 31.1* |
Certification of Chief Executive Officer, Director, and Chairman of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
| 31.2* |
Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
| 32.1** |
Certification of Chief Executive Officer, Director, and Chairman of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
| 32.2** |
Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
| 101.INS |
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
|
| 101.SCH |
Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
|
| 101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document. |
|
| 101.LAB |
Inline XBRL Taxonomy Extension Labels Linkbase Document. |
|
| 101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
|
| 104 |
Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| + |
Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission. |
| # |
Management contract or compensatory plan or arrangement. |
| * |
Filed herewith. |
| ** |
This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.
Date: November 12, 2026
| HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. |
||
| By: |
/s/ Junli He |
|
| Name: |
Junli He |
|
| Title: |
Chief Executive Officer, Director, and Chairman (principal executive officer) |
|
| By: |
/s/ Joseph L. Damasio Jr. |
|
| Name: |
Joseph L. Damasio Jr. |
|
| Title: |
Chief Financial Officer (principal financial and accounting officer) |
|